Source: Annual Congress 2009 - One size (does not) fit all: phenotyping and controlling asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Middelveld, M. Kupczyk, S. E. Dahlén, BIOAIR (Stockholm, Sweden). Oral steroid intervention in severe asthma: focus on phenotypes. Report from the bioair study. Eur Respir J 2009; 34: Suppl. 53, 375

Member's Comments

No comment yet.

Related content which might interest you: Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature Source: Eur Respir J, 52 (4) 1800703; 10.1183/13993003.00703-2018 Year: 2018 4–year trajectory of medication adherence amongst severe asthma patients: Risk factors and impact on asthma control Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Prognosis of new-onset asthma diagnosed at adult age: A systematic review Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Effect of 1 year treatment with inhaled corticosteroids with electronically assessed adherence on height growth in children with asthma Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015 Study to evaluate clinical burden related with oral corticosteroids treatment of severe asthma in Spain (LEVANTE) Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Treatment of severe childhood asthma: what’s the evidence? Source: Annual Congress 2005 - Difficult asthma in children Year: 2005 A new observer independent method to assess therapy response in children with severe asthma based on daily lung function Source: Annual Congress 2013 –Uncontrolled and severe asthma in children Year: 2013 Evaluating the effects of asthma therapy on childhood growth: what can be learnt from the published literature? Source: Eur Respir J 2002; 19: 1179-1193 Year: 2002 Effectiveness of montelukast on asthma control in infants: A claims data study Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Work related symptoms of adult patients with asthma: A multicenter, national, questionnaire based study Source: International Congress 2015 – Work, environment and the epidemiology of asthma Year: 2015 Management of occupational asthma: cessation or reduction of exposure? A systematic review of available evidence Source: Eur Respir J 2011; 38: 804-811 Year: 2011 Effect of not appropriate treatment in severe/not controlled asthma: The AGAVE study Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Evaluating the effects of asthma therapy on childhood growth: principles of study design Source: Eur Respir J 2002; 19: 1167-1178 Year: 2002 X-Tab: Non-interventional study to assess patient-related mid-term outcomes of omalizumab therapy in severe allergic asthmatic patients Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Medication use in children with asthma: a case control study Source: Eur Respir J 2001; 18: Suppl. 33, 329s Year: 2001 Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme Source: Eur Respir J, 55 (6) 1902345; 10.1183/13993003.02345-2019 Year: 2020 A pilot study for markers which can reflect asthmatic activity before and after reduction of inhaled corticosteroids Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases Year: 2013 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014